Dihydropyrimidine déshydrogénase (DPD) : rythme et conséquences

Lévi, 1988, Comparative chronotoxicity of anticancer agents and related mechanisms, Ann. Rev. Chronopharmacol, 4, 283 Lévi, 1997, Randomised multicenter trial of chemotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer, Lancet, 350, 681, 10.1016/S0140-6736(97)03358-8 Levi, 1999, A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucivorin as initial treatment of patients with metastatic colorectal carcinoma, Cancer, 2532, 10.1002/(SICI)1097-0142(19990615)85:12<2532::AID-CNCR7>3.0.CO;2-1 Naguib, 1993, Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases, and dihydrouracil dehydrogenase in mouse liver, Biochemical Pharmacology, 45, 667, 10.1016/0006-2952(93)90141-I Zhang, 1993, Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes : possible relevance to fluoropyrimidine chemotherapy, Cancer Res., 53, 2816 El Khouny, 1990, Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice, Bioch. Pharmacol., 40, 2479, 10.1016/0006-2952(90)90089-4 Duschinsky, 1957, The synthesis of 5 fluoropyrimidines, J. Am. Chem. Soc., 79, 4559, 10.1021/ja01573a087 Podschun, 1989, Purification and characterisation of dihydropyrimidine dehydrogenase from pig liver, Eur. J. Biochem., 185, 219, 10.1111/j.1432-1033.1989.tb15105.x Lu, 1992, Purification and characterisation of dihydropyrimidine dehydrogenase from human liver, J. Biol. Chem., 267, 17102, 10.1016/S0021-9258(18)41899-6 Naguib, 1985, Enzymes of uracil catabolism in normal and neoplastic human tissues, Cancer Res., 45, 5405 Harris, 1988, Circadian rhythm of rat liver dihydropyrimidine dehydrogenase : possible relevance to fluoropyrimidine chemotherapy, Bioch. Pharm., 37, 4759, 10.1016/0006-2952(88)90349-8 Chazal, 1996, Link between dihydropyrimidine deshydrogenase activity in peripheral blood mononuclear cells and liver, Clin. Cancer Res., 2, 507 Etienne, 1994, Population study of dihydropyrimidine dehydrogenase in cancer patients, J. Clin. Oncol., 12, 2248, 10.1200/JCO.1994.12.11.2248 Tuchman, 1985, Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity, N. Engl. J. Med., 313, 245, 10.1056/NEJM198507253130407 Houyan, 1993, Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency, J. Natl. Cancer Inst., 85, 1602, 10.1093/jnci/85.19.1602 Diasio, 1988, Familial deficiency of dihydropyrimidine dehydrogenase, J. Clin. Invest., 81, 47, 10.1172/JCI113308 Harris, 1991, Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome, Cancer, 68, 499, 10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F Fleming, 1993, Dihydropyrimidine dehydrogenase activity in cancer patients, Eur. J. Cancer, 29A, 740 Milano, 1999, Dihydropyrimidine dehydrogenase deficiency and fluorouracil related toxicity, Br. J. Cancer, 79, 627, 10.1038/sj.bjc.6690098 Lu, 1993, Dihydropyrimidine dehydrogenase blood mononuclear cells and liver : population characteristics, newly identified deficients patients, and clinical implication in 5-fluorouracil chemotherapy, Cancer Res., 53, 5433 Petit, 1988, Circadian varying plasma concentration of 5-FU during 5-day continuous venous infusion at constant rate in cancer patients, Cancer Res., 48, 1676 Thiberville, 1994, Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil, Cancer Chemoth. Pharmacol, 35, 64, 10.1007/BF00686286 Metzger, 1994, Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin : relationship with mucosal toxicity in cancer patients, Clin. Pharm. Ther, 56, 190, 10.1038/clpt.1994.123 Flemming, 1994, Circadian variation of 5-fluorouracil (5-FU) and cortisol plasma levels during continuous-infusion 5-FU and leucovorin (LV) in patients with hepatic or renal dysfunction, Proc. Amer. Soc. Clin. Oncol., 13, 352 Bressole, 1999, Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer, Cancer Chemother. Pharmacol., 44, 295, 10.1007/s002800050980 Harris, 1990, Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels : evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion, Cancer Res., 50, 197 Langouët AM, Metzger G, Comisso M, Renée N, Milano G, Mormont MC, et al. Plasma concentration of 5-fluorouracil and mononuclear cell dihydropyrimidine dehydrogenase activity in patients treated with different chronomodulated schedules. Proc. World Conference on Chronobiology and Chronotherapeutics, Ferrara, Italy, 1995, Biol. Rhythm Res., 1995, 26(4), 409 (abstr. 135). Van Kuilenburg, 1998, No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil, Adv. Exp. Med. Biol., 431, 811, 10.1007/978-1-4615-5381-6_156 Tuchman, 1988, Sources of variability of dihydropyrimidine dehydrogenase activity in human blood mononuclear cells, Ann. Rev. Chronopharmacol., 5, 399 Grem, 1997, Inter and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells, Cancer Chemother. Pharmacol., 40, 117, 10.1007/s002800050635